Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
October 04, 2023 07:30 ET
|
Theratechnologies
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14,...
Molecular Diagnostic for Infectious Diseases Market Size Worth $17.61 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
October 03, 2023 09:29 ET
|
The Insight Partners
Pune, India, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Molecular diagnostics is referred to as the detection of genomic variants, aiming to facilitate detection, diagnosis, subclassification, prognosis, and...
Theratechnologies présente ses résultats financiers pour le troisième trimestre et les neuf premiers mois de l’exercice 2023 et fait le point sur ses activités commerciales
September 26, 2023 07:30 ET
|
Theratechnologies
Revenus consolidés de 20,9 millions de dollars et BAIIA ajusté de 2,2 millions de dollars au troisième trimestre de 2023Dépôt d’une sBLA relative à la formulation F8 de la tésamoréline auprès de la...
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
September 26, 2023 07:30 ET
|
Theratechnologies
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 millionsBLA for F8 formulation of tesamorelin submitted to FDAAgreement in principle on key amendments to loan facility with...
Theratechnologies soumet un supplément à la licence de produit biologique (sBLA) pour la formulation F8 de la tésamoréline aux fins d’examen par la FDA
September 25, 2023 07:00 ET
|
Theratechnologies
La formulation F8 vise à remplacer EGRIFTA SV® par une posologie simplifiée pour le traitement de l’excès de graisse abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie. ...
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
September 25, 2023 07:00 ET
|
Theratechnologies
F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) --...
Infectious Disease Diagnostics Market to Hit $37.94 Billion, Globally, by 2028 – Exclusive Report by The Insight Partners
September 20, 2023 10:22 ET
|
The Insight Partners
Pune, India., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tuberculosis (TB) is the 13th most significant cause of mortality globally and the second leading infectious disease after COVID-19, according to the...
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
September 20, 2023 08:00 ET
|
Vir Biotechnology, Inc.
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation,...
Theratechnologies annoncera ses résultats du troisième trimestre de l’exercice financier de 2023
September 18, 2023 16:15 ET
|
Theratechnologies
MONTRÉAL, 18 sept. 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement...
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
September 18, 2023 16:15 ET
|
Theratechnologies
MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...